Callisto Cites New Research Data on Cancer Drug Atiprimod in Presentations at American Society of Hematology Meeting
15th Dec 2005, 13:10 GMT
Callisto Pharmaceuticals, a developer of new drug technologies in the fight against cancer and other serious healthcare threats, has released additional clinical research data on its cancer drug candidate Atiprimod, and further announced plans to extend the present Phase I/IIa clinical trial in multiple myeloma patients to higher drug dosages to obtain a maximum tolerated dose, and further evaluate patients for drug efficacy.
Callisto Cites New Research Data on Cancer Drug Atiprimod in Presentations at American Society of Hematology Meeting related news:
- Dacogen Injection Data Presented at American Society of Hematology Annual Meeting — Laboratory News from StratCenter.com
- Ascenta AT-101 Data Presented at the American Society of Hematology 47th Annual Meeting and Exposition in Atlanta, GA — Bio-Technology News from StratCenter.com
- BioCryst Announces Presentation of Fodosine Data During the 47th Annual Meeting and Exposition of the American Society Of Hematology — Laboratory News from StratCenter.com
- Web Alert: Callisto to Host Investor Conference Call to Discuss Developments in Anti-Cancer Drug Trials and IP Growth — Operations-Related News from StratCenter.com
- Geron Announces Data on the Effects of Its Cancer Drug, GRN163L, on Multiple Myeloma at the American Society of Hematology Annual Meeting — Laboratory News from StratCenter.com
- Vion Presents Cloretazine Data at ASH Annual Meeting — Laboratory News from StratCenter.com
- REVLIMID Clinical Results as Oral Treatment Regimen in Myelofibrosis Presented at the 47th American Society of Hematology Meeting — Laboratory News from StratCenter.com
- REVLIMID Clinical Results as Oral Treatment Regimen in Chronic Lymphocytic Leukemia Presented at the 47th American Society of Hematology Meeting — Laboratory News from StratCenter.com
- Cytokinetics Announces 7 Poster Presentations at the 45th Annual American Society of Cell Biology Meeting — Cardiology News from StratCenter.com
- REVLIMID Clinical Results as Oral Treatment Regimen in Newly Diagnosed Multiple Myeloma Presented at the 47th American Society of Hematology Meeting — Pharmaceuticals News from StratCenter.com
Latest news from Laboratory News from StratCenter.com:
- Abstract Evaluating QUADRAMET for Multiple Myeloma Presented erican Society of Hematology Annual Meeting
- QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- Stratagene Reports Q3 Results
- Viking Systems Appoints Dr Michael Manyak to Its Board
- Soliant Health To Exhibit at the American Speech-Language-Hearing Assoc Conference
- Sysmex America Awarded Contract to Service VA Med Cntrs in Midwest States
- Ronald D Luff, MD, Recognized By the American Society of Cytopathology for Groundbreaking Work in Diagnosis of Cervical Disease
- INNOVIVE Pharmaceuticals Reports Q3 Results
- Launch of 'Egg Banking' Program Breaks New Ground as 1st Program of Its Kind in NC
- Global Care Quest Announces ICIS 5